NL0015000DX5

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

July 25, 2025 16:05 ET  | Source: atai Life Sciences Initial results demonstrate numerical improvement of cognitive and functional measures…

4 months ago